REG - Futura Medical PLC - Futura Medical plc Total Voting Rights

Futura MedicalAnnouncement

30/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211130:nRSd9324Ta&default-theme=true

RNS Number : 9324T  Futura Medical PLC  30 November 2021

30 November 2021

 Futura Medical plc

("Futura" or the "Company")

Total Voting Rights

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products for sexual health and pain relief, for the purposes of
the FCA's Disclosure and Transparency Rules, the Company's total issued share
capital at the date of this announcement is 287,150,971 Ordinary Shares.

 

Since the Company currently holds no shares in treasury, the total number of
voting rights in the Company is 287,150,971 and this figure may therefore be
used by shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a change
in their interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.

 

ENDS

 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:

Liberum

Richard Lindley/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com (mailto:ziylo@optimumcomms.com)

Tel: +44 (0) 20 3922 0891

 

Notes to editors:

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys(®) technology. Each DermaSys(®) formulation is separately
patented and specifically tailored for the selected indication and
application, as well as being optimised for clinical efficacy, safety,
administration and patient convenience. The products are developed for the
prescription and consumer healthcare markets as appropriate. Current
therapeutic areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed to maximise
product differentiation and value creation whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction (ED) through a unique evaporative mode of action.
Futura has conducted a Phase 3 study using MED3000 in ED, referred to as
"FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment baseline,
consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over 60% of
patients experiencing a clinically meaningful improvement in their ED.
MED3000 also begins to work immediately in some patients, with 60% of patients
seeing onset of their erection within 10 minutes of application. MED3000 is
CE marked in Europe and the UK as a clinically proven topical
treatment for adult men with erectile dysfunction.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBLBDBSBDDGBC